Change in role from Chief Data Officer reflects Qureight’s continued growth and commercial success in delivering customers’ clinical studies
Qureight, a techbio company advancing the understanding of lung and heart disease through application of its AI-powered CT imaging biomarkers and clinical data management platform in clinical trials, today announced the appointment of Dr Steven Bishop as Chief Medical Officer (CMO). Previously Chief Data Officer, Steven’s new role reflects changes in company structure, in response to continued growth and commercial success.
As CMO, Steven will lead Qureight’s Clinical Operations team, the team responsible for delivering customers’ global clinical studies. Having worked previously to reshape the Company’s product offering, moving forward, he will lead Qureight’s product development and clinical strategy, to ensure that Qureight continues to lead the field and meet market needs. Steven will also work closely with colleagues in the business development team and lead Quality Assurance and Regulatory Affairs.
Steven has over 20 years of experience in healthcare and data science, including building AI solutions in both medtech and healthtech fields, and has published in the domains of critical care pathophysiology and surgical data science. As Chief Data Officer for Qureight, he was responsible for ensuring that Qureight’s AI and imaging biomarker models are trained on the best quality data. He was also in charge of maintaining and extending Qureight’s global network of data relationships, which span NHS Trusts, hospital groups, contract research organisations and industry. Prior to joining Qureight, Steven was Head of Research and Strategy at CMR Surgical, and Director of Clinical, Regulatory and AI at Flok Health. He has an undergraduate degree in computer science, as well as a medical degree from the University of Cambridge. He has also undertaken academic and specialist training in anaesthesia and intensive care medicine, and is a Fellow of the Royal College of Anaesthetists.
Muhunthan Thillai, MD, Co-founder and CEO, Qureight, commented: “Steven has proven himself to be an invaluable member of the Qureight leadership team since he joined 18 months ago. His new role as CMO is reflective both of the progress of the company, and of his significant contributions to our success. Our team now has the infrastructure, operational processes, capability and compliance to lead global clinical studies. I look forward to working with him in his new role to grow and develop Qureight further to become an imaging world leader for clinical trials.”
Dr Steven Bishop, Chief Medical Officer, Qureight, added: “I first joined Qureight as it was clear that the potential impact of the platform, to support clinical trials and ultimately increase treatment options for patients, was huge. It has been a real pleasure to work with such a committed and knowledgeable team over the past 18 months, and I’m both delighted and excited to be moving into this new role.”
